ProAir Digihaler in COPD Disease Management: A Real World Study
ProAir Digihaler in COPD Disease Management: A Real World Study to Assess ProAir Digihaler Inhalation Parameters Thresholds and Their Use to Identify Deterioration in Clinical Practice
Sponsor: Pulmonary Research Institute of Southeast Michigan
Listed as NCT04821869, this observational or N/A phase trial focuses on COPD and COPD Exacerbation Acute and remains completed. Sponsored by Pulmonary Research Institute of Southeast Michigan, it has been updated 9 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Jul 2025 — Present [monthly]
Completed
-
Sep 2024 — Jul 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2022 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting
▶ Show 4 earlier versions
-
Jan 2022 — May 2022 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Jun 2021 — Jan 2022 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Pulmonary Research Institute of Southeast Michigan
- Teva Branded Pharmaceutical Products R&D, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .